Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Executive Summary
FDA considering public statement reflecting its view that biosimilars not deemed interchangeable will not be substituted at pharmacy, but the extent such a statement would limit payer-driven practice remains in question.